膜杰作
Star Staining
组分（Materials Provided）
| ID | Components | Size |
| ADC-P009-C01 | 20 x Reaction buffer | 100ul |
| ADC-P009-C02 | Cofactor A | 50ul |
| ADC-P009-C03 | Cofactor B | 50ul |
| ADC-P009-C04 | Substrate A | 120ul |
| ADC-P009-C05 | Substrate B | 120ul |
| ADC-P009-C06 | Enzyme A | 120ul |
| ADC-P009-C07 | Enzyme B | 120ul |
| ADC-P009-C08 | Enzyme C | 40ul |
| ID | Components | Size |
| ADC-P009-1-C01 | Binding buffer | 15ml |
| ADC-P009-1-C02 | Elution buffer | 2ml×2 |
| ADC-P009-1-C03 | Neutralization buffer | 1ml |
| ADC-P009-1-C04 | 250 mM Tris-HCl buffer (pH7.5) | 1.5ml |
| ADC-P009-1-C05 | 10×PBS (pH7.2- 7.4) | 6ml |
| ADC-P009-1-C06 | Desalting column | 2per |
| ADC-P009-1-C07 | Concentrator tube | 2per |
| ADC-P009-1-C08 | ProteinA Resin | 100ul×5 |
背景（Background）
Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.
应用说明（Application）
AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 5mg) is designed to conjugate 5mg mAb with toxic payload (MMAE) through site-specific enzymatic reaction.
It is for research use only.
优势特色（Features）
- Site-specific conjugation through Fc-glycan with high conjugation efficiency
- Uniform DAR value and highly homogeneous ADC products
- No need of amino acid sequence engineering
- Easy to use: One-pot & One-step
- Two options: DAR2 & DAR4 ADC product
存储（Storage）
BoxA: The unopened kit is stable for 12 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table. BoxB: The unopened kit is stable for 12 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.
典型数据-Typical Data Please refer to DS document for the assay protocol.
ADC DAR value assessment by RP-HPLC
DAR (Drug Antibody Ratio) value of ADC product was analyzed by RP-HPLC (QC tested).
Column: TSK gel Butyl-NPR column (4.6 mm × 35 mm, 2.5μm; TOSOH)
Mobile phase A：20 mM sodium phosphate, 1.5 M ammonium sulfate (pH 6.9)
Mobile phase B：75% (v/v) 20 mM sodium phosphate, 25% (v/v) isopropanol (pH 6.9)
Flow rate: 0.4 mL/min
Column temperature: 30 °C Detection wavelength：280nm
Loading Amount:10 µg (5-10 µL)
DAR (Drug Antibody Ratio) value of ADC product was analyzed by RP-HPLC (QC tested).
DAR4 =(0*1.5+1*4.38+2*2.25+3*7+4*84.88)/100=3.694
DAR2＝(0*0.52+2*99.48)/100=1.9896
ADC DAR value assessment by RP-HPLC
DAR (Drug Antibody Ratio) value of ADC product was analyzed by RP-HPLC (QC tested).
Column: TSK gel Butyl-NPR column (4.6 mm × 35 mm, 2.5μm; TOSOH)
Mobile phase A：20 mM sodium phosphate, 1.5 M ammonium sulfate (pH 6.9)
Mobile phase B：75% (v/v) 20 mM sodium phosphate, 25% (v/v) isopropanol (pH 6.9)
Flow rate: 0.4 mL/min
Column temperature: 30 °C Detection wavelength：280nm
Loading Amount:10 µg (5-10 µL)
DAR (Drug Antibody Ratio) value of ADC product was analyzed by RP-HPLC (QC tested).
DAR4 =(0*1.5+1*4.38+2*2.25+3*7+4*84.88)/100=3.694
DAR2＝(0*0.52+2*99.48)/100=1.9896
Statement of Rights
AGLink products are co-developed by ACROBiosystems Co., Ltd. and Glyco-therapy Biotechnology Co., Ltd. based on Glyco-therapy's conjugation platform (YTConju™) and are not authorized for commercial use. The sale and use of AGLink products doesn't represent any forms of license or authorization of the attached technologies for developing any diagnostic, therapeutic or prophylactic products for commercial purposes.
Note of application
AGLink products are intended for research use only by the Buyer or its users and can not be used for any other purposes, including, but not limited to, use for any clinical diagnostic type use, in vitro or in vivo therapeutic use, prophylactic use, any type of consumption or application to human or animals.
